NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
NHS England · awarded 31 May 2024 · delivered in East Midlands
£765.0m
Award value
£765,000,000
9
Suppliers
Recorded as a large business
30 Apr 2027
Runs until
from 1 Jul 2024
Who
| Buyer | NHS England Runcorn |
|---|---|
| Suppliers |
Bio Products Laboratory Ltd CSL Behring UK Ltd LFB Novo Nordisk Octapharma Limited Pfizer Ltd Roche Products Ltd Sobi (Swedish Orphan Biovitrum Ltd) Takeda UK Ltd |
| Category | goods |
| Classification | Pharmaceutical products CPV 33600000 |
| Notice published | 24 July 2024 |
What it is for
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024 Offer reference number: CM/PHS/22/5661 Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Read the original award notice on Contracts Finder →
Other contracts from this buyer
1269 awards on file, worth £50.2bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 4 Mar 2026 | New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland | NHS England | Willmott Dixon Construction Limited +9 | £37.0bn |
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
Everything NHS England has awarded →
Other contracts won by this supplier
11 awards on file, worth £3.6bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
| 22 Jul 2024 | NHS Branded Medicines Tranche Framework for London and South of EnglandEast Midlands | NHS England | Sun Pharma UK Ltd +28 | £381.0m |
| 25 Jun 2025 | NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National | NHS England | Roche Products Ltd +27 | £261.9m |